“During Markus Granlund’s tenure as Interim CEO, he has demonstrated the solid leadership and strategic vision relevant for TFS to further develop as a leading global mid-size contract research organization. Markus’ focus on operational efficiency has already successfully driven measurable improvements across the company,” says Katarina Ageborg, Chairman of the TFS Board of Directors since February 2025.

“I am honored to take on the role as permanent CEO and look forward to continuing to lead TFS alongside my passionate and dedicated colleagues. With our newly designed and therapeutically aligned structure, we’re well-positioned to deliver even greater value to our clients, focusing our talent and expertise where it matters most. I believe deeply in the power of meaningful partnerships, impactful science, and our shared commitment to the patients whose lives we aim to improve, and I’m proud to continue that work with such a committed team,” says Markus Granlund, CEO, TFS.

About TFS HealthScience
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 50 countries, TFS and its strategic partners provide tailored strategic resourcing solutions and clinical development services in specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. Dedicated to empowering partners and enriching lives, TFS offers flexible solutions that combine global reach with the agility and responsiveness of a mid-sized CRO.

For more information, please contact:
Katarina Grönwall, VP Communications & Sustainability
+46 70 300 35 38, katarina.gronwall@ratos.com